RxDoctor Payments Data

Laurie Boyd, NP

Nurse Practitioner · Adrian, MINPI 1356328124

Payments from drug & device makers

$1,896in general payments, 2019–2025

Across 83 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$483
  • Otsuka America Pharmaceutical, Inc.$313
  • AbbVie$302
  • Neurocrine Biosciences, Inc.$258
  • E.r. Squibb & Sons, L.L.C.$102
  • GSK$79
  • plus $359 from 9 others

What the payments were for

  • Food & beverage$1,888100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,896 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$13,924
Medicare patients
26
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole64$104,247
VraylarCariprazine Hcl25$37,202
TrintellixVortioxetine Hydrobromide11$12,349
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$2,225
Lamotrigine ErLamotrigine21$2,095
Bupropion XlBupropion Hcl77$1,565
Fluoxetine Hcl38$1,404
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine64$1,245
Oxcarbazepine24$908
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$643
Mirtazapine31$635
Lurasidone Hcl23$607
Hydroxyzine Hcl43$593
Duloxetine Hcl54$552
Trazodone Hcl88$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$313$104,24764 claims
AbbVieVraylar$302$37,20225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Adrian

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →